Overview

A Bioequivalence Study Between Capozide Versus ACE-Hemmer-ratiopharm in Healthy Adult Participants Under Fasting Conditions

Status:
Not yet recruiting

Trial end date:
2022-01-28

Target enrollment:

Participant gender:

Summary

This is a bioequivalence study to compare Capozide (test product [T]) to ACE-Hemmer-ratiopharm (reference product[R]) produced by Ratiopharm GmbH Germany in healthy adult participants under fasting conditions. ACE-Hemmer-ratiopharm®is the registered trademark of Ratiopharm GmbH Germany.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Captopril, hydrochlorothiazide drug combination